Similarly, the PS T cell DEGs set showed a predictive value for patient response in three melanoma cohorts treated with anti-PD1 therapy (Liu2019_PD1_Melanoma) and anti-CTLA4 therapy (VanAllen2015_CTLA4_Melanoma and Nathanson2017_CTLA4_Melanoma_Post) (Fig. 6C, and S6B). This evidence concerns the gene PDCD1 and melanoma.